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Abstract 
Background: We aimed to clarify the incidence and the clinico-pathological value of non-
muscle myoglobin (Mb) in a large cohort of non-invasive and invasive breast cancer 
cases. 
Methods: Matched pairs of breast tissues from ten patients plus 17 breast cell lines were 
screened by qPCR for Mb mRNA. Additionally, 917 invasive and 155 non-invasive breast 
cancer cases were analysed by immunohistochemistry for Mb expression and correlated 
to clinico-pathological parameters and basal molecular characteristics including 
ER/PR/HER2, FASN, HIF-1, HIF-2, GLUT1 and CAIX. The spatial relationship of Mb 
and ER or FASN was followed up by double immunofluorescence. Finally, the effects of 
estradiol treatment and FASN inhibition on Mb expression in breast cancer cells were 
analysed. 
Results: Mb mRNA was found in a subset of breast cancer cell lines, in microdissected 
tumors Mb was markedly upregulated. 71% of tumors displayed Mb expression in 
significant correlation with a positive hormone receptor status and better prognosis. In 
silico data mining confirmed higher Mb levels in luminal type breast cancer. Mb was also 
correlated to FASN, HIF-2 and CAIX, but not to HIF-1 or GLUT1, suggesting hypoxia 
to participate in its regulation. Double-immunofluorescence demonstrated a cellular co-
expression of ER or FASN and Mb. Also, Mb levels were modulated upon estradiol 
treatment and FASN inhibition in a cell model. 
Conclusion: We conclude that in breast cancer Mb is co-expressed with ER and co-
regulated by estrogen signaling and can be considered a hallmark of luminal breast 
cancer phenotype. This and its possible new role in fatty acid metabolism may have 
fundamental implications for our understanding of Mb in solid tumors. 
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1. Introduction 
Human myoglobin (Mb) is considered one of the best characterized proteins with 
more than 11,200 PubMed-listed publications since Kendrew et al. have presented the 
first three dimensional model of this molecule in 1958 (Kendrew, 1958). It is commonly 
described as a cytoplasmic hemoprotein that is solely occurring at milli-to micromolar 
concentrations in cardiac myocytes and type I and IIa skeletal muscle fibers of mammals. 
In myocytes, Mb is widely accepted to function as  temporary “store” for oxygen, able to 
buffer short phases of exercise-induced increases in O2 flux during which it supplies the 
gas to mitochondria (Ordway & Garry, 2004). Another, more controversially discussed 
role is Mbs´ facilitation of oxygen diffusion within muscle cells (Jürgens et al, 1994; 
Wittenberg, 1970). Although Mb knockout mice exhibited normal exercise capacity and 
no signs of compromised cardiac energetics due to multiple systemic compensations 
(Garry et al, 1998; Gödecke et al, 1999), follow-up studies stressed the importance of 
functional Mb in maintaining nitric oxide (NO) homeostasis in muscle through either 
scavenging (Flögel et al, 2001) or producing the NO molecule (Hendgen-Cotta et al, 
2008). That way, Mb might participate in tuning vasodilatory responsiveness and 
protecting the respiratory chain from NO inhibition (Brunori, 2001). Further possible 
functions of Mb in muscle include synthesis of peroxides (Khan et al, 1998), scavenging 
of reactive O2 species (Flögel et al, 2004) and binding of fatty acids (Masuda et al, 2008). 
In humans, Mb is synthesized at concentrations of ~200-300 M in striated muscle 
and, albeit at much lower levels, in a variety of human tumors including 
medullomyoblastoma (Smith & Davidson, 1984), thymolipoma (Iseki et al, 1990), acute 
leukaemia (Ruck et al, 1995) and desmoplastic small round cell tumors (Zhang et al, 
2003). Following an accidental observation of positive Mb staining in several human 
carcinomas in 2001, we have since then systematically examined Mb expression in 
human breast cancer. Very recently, Flonta et al. described Mb in solid tumors including 
31 breast cancer cases, however, this small cohort size precluded further statistical 
analyses (Flonta et al, 2009). Now, we are presenting the first comprehensive analysis of 
Mb expression in a large and representative cohort of human breast tissues 
encompassing normal tissue (n=56),  Ductal Carcinoma in Situ (DCIS, n=155), invasive 
breast cancer (n=917) and breast cancer recurrences (n=76), enabling a portrayal of the 
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associations between clinico-pathological parameters and the range of Mb synthesis 
seen in mammary carcinomas. We also shed some light on unusual functions of Mb in 
cancer by looking at the impact of steroids on the steady state level of the protein and by 
examining Mb´s involvement in fatty acid metabolism. 
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2. Material and methods 
 
2.1 Clinical materials/Patients 
The matched tumor/normal samples of invasive ductal breast carcinomas and 
corresponding normal breast epithelium (n=10) analyzed in this study, have recently been 
described (Veeck et al, 2006). For immunohistochemistry, our study included tissue micro 
arrays of normal tissue, intratumoral ductal carcinoma in situ (DCIS), invasive breast 
cancer and breast cancer recurrences of patients diagnosed at the Institute of Surgical 
Pathology (University Hospital, Zurich, Switzerland), as described (Theurillat et al, 2007). 
Tumor histology was determined according to the criteria of the World Health 
Organization (2003), staging the disease followed UICC guidelines (2002). Tumors were 
graded according to Bloom and Richardson, as modified by Elston and Ellis (Elston & 
Ellis, 1993). Clinico-pathological characteristics of the patients/tumors are given in Table 
1. For statistical analysis, only cases with clinical follow-up data were considered. The 
median observation time for overall survival was 59 months for patients still alive at the 
time of analysis. Two-hundred-and-twenty-five patients (24%) died during follow-up. Data 
on adjuvant therapy was not available. Appropriate review board consent has been 
obtained to allow use of these materials for research purposes. 
 
2.2 Cell lines 
The human mammary epithelial cell line MCF12A as well as the breast cancerous 
cell lines BT20, BT474, Cal51, EFM19, HBL100, Hs578T, MDA-MB231, MDA-MB361, 
MDA-MB453, MDA-MB415, MDA-MB436, MDA-MB468, MCF7, SKBR3, T47-D and 
ZR75-1 were obtained from the ATCC (Rockville, MD, USA) and cultured under 
recommended conditions.  
 
2.3 Quantitative real-time reverse transcription PCR 
For qPCR experiments we used the ABI Prism 7500 Fast SDS (Applied Biosystems, 
Darmstadt, Germany) with the following primers:  MB (111bp) 5´- 
GGCATCATGAGGCAGAGATT – 3´ and 5´- TCTGCAGAACCTGGATGATG – 3`, 
GAPDH (289bp) 5’-GAAGGTGAAGGTCGGAGTCA-3’ and 5’-
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TGGACTCCACGACGTACTCA-3’, ß-Actin (185bp) 5’- GGACGACATGGAGAAAATC-3’ 
and 5’- ATAGCACAGCCTGGATAGC-3’. 
 
 
2.3 Western blots 
MDA-MB468 cells were harvested with a lysis buffer containing 0.1% NP-40, 
400mM NaCl, 1mM EDTA (pH8.0), 10mM Tris-HCl (pH8.0) and protease inhibitors. 
Protein extracts were electrophoresed on a 15% SDS-PAGE gel. Monoclonal antibody 
mouse anti-myoglobin (clone Z001, Zymed Laboratories, USA) was used for 
immunoblotting (1:1000 dilution). For equal loading control, blots were stripped and re-
probed by monoclonal antibody mouse anti--actin at a 1:5000 dilution (#A5441, Sigma-
Aldrich, Basel, Switzerland).  
 
2.4 Immunohistochemistry and immunofluorescence 
Tissue sections were processed using automated immunohistochemistry platforms 
(BOND, Labvision; Benchmark, Ventana) using the following antibodies and dilutions: 
Mb, clone Z001, Zymed Laboratories, USA (1:300). FASN, clone 3F2-1F3, Abnova, 
Taipeh, Taiwan (1:2000). HIF-1, clone mgc3, Abcam, Cambridge, UK (1:400). HIF-2, 
rabbit polyclonal, Novus Biologicals, Littleton, USA (1:150). GLUT1, rabbit polyclonal, 
Chemicon, Temecula, USA (1:1000). CAIX, rabbit polyclonal, Abcam, Cambridge, UK 
(1:300).  Immunohistochemistry was evaluated by two clinical pathologists (GK, FFR). 
Intensity of Mb, GLUT1, CAIX and FASN was semiquantitatively scored as negative, 
weakly, moderately or strongly positive (0 to 3+). ER/PR/HIFs were evaluated in percent 
of positive nuclei. Double Immunofluorescence (Mb/ER and Mb/FASN) was performed as 
described (Kristiansen et al, 2008). 
 
2.5 Electron Microscopy (EM) 
Tissues from two breast tumors were fixed with 2.5% glutaraldehyde, postfixed 
with osmium tetroxide, embedded in epoxy resin, cut with an ultramicrotome, mounted on 
200 mesh copper grids, stained with uranyl acetate and lead citrate and examined with a 
Zeiss EM10 transmission electron microscope (Zeiss, Oberkochen, Germany) at 60 kV. 
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2.6 Expression of Mb gene after incubation of MCF-7 cells with ß-Estradiol 
MCF7 cells (8x105) were seeded into a 10cm culture dish and 24h later 17-
ß-estradiol (Sigma-Aldrich, Deisenheim, Germany) dissolved in 5 µl ethanol abs., was 
applied to the cells at a final concentration of 0 pM, 20 pM, 40 pM and 60 pM. Cells 
without 17-ß-estradiol and Ethanol served as internal control.  
 
2.7 Expression of Mb gene after incubation of MDA-MB-468 cells with the FASN inhibitor 
C75 
3x105 MDA-MB-468 cells were seeded into 6 well-plates and exposed to 10 g/ml 
final concentration of the FASN inhibitor C75 (Sigma-Aldrich, St. Louis, MO, USA) for 8, 
24 and 48h. RNA and proteins were isolated following standard procedures. 
 
2.8 Statistical Analysis 
Expression data were analyzed with the software package SPSS, version 16.0 
(SPSS Inc., Chicago, USA). Fisher’s exact and chi-square tests for trends were used to 
assess the statistical significance of associations between Mb expression and clinico-
pathological parameters (Tab. 1). Univariate survival analysis was performed with 
univariate Cox analyses and Kaplan-Meier curves (Log rank test). Bivariate correlations 
according to Spearman were applied to the immuno-intensity of normal tissue, intraductal 
and invasive carcinomas. 
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3. Results    
 
3.1 Human breast cancer tissue exerts a complex pattern of Mb expression  
3.1.1 Mb is detectable on mRNA level in cell lines and human breast tumors 
Following the initial observation of Mb immunoreactivity in conventional immuno-
histochemistry analyses, Mb transcript levels were determined in breast biopsies and 
breast cell lines. Whereas low levels of Mb mRNA were detectable in four of ten cases of 
healthy breast tissue (Fig. 1A), Mb expression was upregulated in nine of ten matched 
normal / tumor tissue samples with a median tumor-to-normal up-regulation of 352 fold. 
With regard to breast cell lines, Mb mRNA was not detectable in benign MCF12A 
epithelial cells as well as in MDA-MB436, Hs578T, Cal51 tumor cells (Fig. 1B). Ten 
breast cancer cell lines (MDA-MB231 to MCF7, Fig. 1B) expressed detectable but low 
amounts of Mb mRNA while three breast cancer cell lines contained abundant quantities 
of the Mb transcript, i.e. EFM19, MDA-MB415 and MDA-MB468 cells. Regarding the 
protein abundance, we used a commercial chemiluminescence based Mb-assay and 
determined the amount of Mb protein present in normoxic 106 MDA-MB468 cells to 
correspond to ~65 ng or 4 pmol (assuming a mean cell size of 20 micrometer and sphere 
shaped cells).  
 
3.1.2 Large scale immunohistochemical analysis of Mb protein in breast tissues 
Using a validated monoclonal Mb antibody (Fig. S1), we next analysed Mb 
expression on tissue microarrays containing normal tissue (n=56), intratumoral ductal 
carcinoma in situ (DCIS; n=155), invasive breast cancer (n=917, clinico-pathological 
parameters are given in Table 1) and 76 recurrences of invasive tumors. In normal breast 
tissue, staining was observed in secretory luminal epithelial cells, but not in myoepithelial 
cells (Fig. 1C, arrowhead), with single secretory cells (bold arrow) staining considerably 
stronger than adjacent secretory cells (Fig. 1C, thin arrow). Altogether, in normal breast 
seven percent of cases were completely negative for Mb, 49% were weakly positive, 39% 
stained moderately positive and five percent of tissues stained strongly (Fig. S2). DCIS 
showed altogether a more abundant Mb staining (Fig. 1D): 12% of DCIS cases were 
negative, 38% weakly positive, 39% moderately positive and 11% were strongly positive. 
In invasive carcinoma, the number of Mb negative cases was markedly higher than in 
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normal tissue: 29% were negative, 32% were weakly positive, 30% were moderately 
positive (Fig. 1E) and 9% were strongly positive (Fig. 1F). A spotted, mosaic like 
expression pattern was frequently seen in DCIS and invasive carcinoma (Fig. 1E). In 
tumor recurrences, 30% cases were Mb negative, 22% weakly positive, 33% moderately 
positive and 15% stained strongly (Fig. S2 ). Apparently, although the mean Mb positivity 
is not significantly altered during malignant progression, an increasing polarization in Mb 
expression is noted in the increased number of negative and strongly positive cases from 
normal tissue to tumor recurrences. 
 
3.2 Electron microscopy: Mb is found without striated muscle elements 
Since myoglobin has been described as a marker of rhabdomyoid differentiation, 
we analyzed two breast tumors with strong Mb immunoreactivity by transmission electron 
microscopy (Fig. S3A/B). However, no striated muscle elements could be observed in 
these cases, suggesting that increased expression of Mb occurs independently of 
rhabdomyoid tumor differentiation.  
 
3.3 Myoglobin expression in invasive breast cancer shows a complex correlative pattern 
to endogenous markers of Hypoxia (HIF-1, HIF-2, GLUT1 and CAIX) 
A subset of invasive breast cancer cases (n=150) was additionally analyzed for 
protein level expression of the hypoxia inducible (transcription) factors 1 and 2 (HIF-
1, HIF-2) which are generally considered the key regulators of the hypoxic response in 
cells and tissues, and their target genes glucose transporter 1 (GLUT1) and carbonic 
anhydrase IX (CAIX). Mb expression correlated significantly with HIF-2 and CAIX but 
failed to correlate with HIF-1 or GLUT1 (Table 2). 
 
3.4 Tumor-derived myoglobin expression is linked to estrogen receptor status and better 
prognosis and may present a marker for luminal type breast cancer 
In invasive breast carcinomas Mb expression was associated with better 
histological tumor differentiation according to BRE-grading (correlation coefficient (cc) =-
0.116, p=0.001). Mb did not correlate with pT stage, nodal status or tumor type. Mb 
expression was positively correlated with estrogen (ER) and progesterone receptor (PR) 
positivity (cc=0.206, p=0.001 and cc=0.180, p=0.001) and negatively with the 
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myoepithelial/basal phenotype marker CK5/6 (cc=-0.120, p=0.001). No significant 
correlation was found with Her2, Ki-67 fraction or CD34-microvessel density.  
Towards the prognostic value of Mb and clinico-pathological parameters, a 
univariate Cox analysis confirmed histological tumor grade, pT stage, nodal status and 
hormone receptor (ER/PR) status as significant predictors of overall survival in our 
patient cohort (Supplemental Table 1). High Mb expression was also significantly 
associated with longer overall patient survival (five-year survival rate of Mb-pos. cases 
83% vs. 75% in Mb-negative cases, Fig. 2A) but lost significance in a multivariate Cox 
analysis which included pT, pN, BRE-grade, ER and Mb (not shown). In a multivariate 
survival analysis restricted to ER, PR (as markers of luminal phenotype) and Mb, only 
PR remained a significant prognosticator (HR=0.62, p=0.004), whereas Mb yielded a 
trend towards a prognostic value (HR =0.75, p=0.06) and ER showed none at all 
(HR=0.74, p=0.11). However, in a Kaplan Meier analysis stratifying tumors in groups that 
were either a) negative for ER and Mb, b) positive for ER or Mb or c) positive for both 
ER and Mb, it became apparent that Mb does add some prognostic information to the 
ER status (Fig. S4), since tumors that were either positive for Mb or ER showed an 
intermediate course in comparison to tumors that were negative or positive for both 
markers (p=0.001). 
We additionally classified Mb levels in correlation with a publically available breast 
cancer expression dataset (Farmer et al, 2005) (GEO Profiles, 
http://www.ncbi.nlm.nih.gov/sites/entrez, GDS1329). Here, Mb levels are significantly 
higher (p=0.005, Kruskal-Wallis test) in the group of luminal tumors compared to basal or 
apocrine types. These findings along with the positive correlation of Mb with ER, the 
better tumor differentiation with improved prognosis, and the negative correlation with the 
basal phenotype marker CK5/6 all point to Mb as a marker of luminal tumor 
differentiation. This association of Mb with characteristics of the luminal tumor subtype, 
namely ER positivity led us to investigate this point further.  
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3.6 Mb expression is regulated by estrogen signaling in silico and in vitro and co-localizes 
with the estrogen receptor 
Publically available DNA array expression data (Geoprofiles, GDS2324) (Coser et 
al, 2003) had already indicated a tight co-regulation of Mb and ER mRNAs in the breast 
cancer cell line MCF7 by showing that estrogen starvation was able to induce, while 
estrogen application suppressed, Mb and ER transcripts in either a time or dose 
dependent manner (Fig. S5; ER = ESR1 in figure). We repeated this experiment and 
could confirm the in silico data also in vitro in that application of 17--estradiol to ER 
positive MCF7 breast cancer cells repressed Mb expression dose dependently (Fig. 2B). 
This co-silencing of ER and Mb expression by estrogen application to a breast 
cancer cell line prompted us to analyze the spatial association of both proteins by double 
immunofluorescence. In normal lobular breast parenchyma, approximately 90% of the 
strongly Mb positive secretory cells interspersed in the secretory cell layer that we had 
already noted in the chromogenic immunohistochemistry, demonstrated a cellular co-
localisation (Fig. 2E, left) of cytoplasmic Mb (Fig. 2C, left) and nuclear ER (2D, left) 
staining. In invasive breast carcinomas, this co-expression still was apparent in well 
differentiated carcinomas (2E, right), whereas in moderately-poorly differentiated tumors 
this overlap was less prominent (not statistically evaluated). 
 
 
3.7 Non-respiratory functions of non-muscle Mb? 
The amount of Mb detected in human breast cancer tissue and MDA-MB468 cells 
was similar in Western blot analysis (data not shown) and equaled 65 ng per 106 tumor 
cells as described above. Since this minute amount of Mb is unlikely to play a significant 
role in the maintenance of cellular oxygenation, Mb functions alternative to respiration 
support have to be considered. Recently, Mb was described again as a fatty acid (FA) 
binding protein and suggested to have a role in the transport of FAs in oxygenated cells 
(Gloster & Harris, 1977; Masuda et al, 2008; Yackzan & Wingo, 1982). This prompted us 
to investigate the possible co-localization of Mb and fatty acid synthase (FASN) in both 
healthy and cancerous breast tissue. FASN catalyses the synthesis of unbranched fatty 
acids and is upregulated in the broad majority of malignant tumors (Menendez & Lupu, 
2007). In a direct comparison of FASN expression with Mb in a subset (n=293) of our 
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breast cancer cohort, a highly significant correlation of both proteins was found 
(CC=0.297, p=0.001). Moreover, in normal breast tissues, again, a striking spatial 
concordance in the expression of Mb and FASN was seen (Fig. 3A-C, left), which was 
also partially retained in cancer (Fig. 3A-C, right).  
To check for a possible functional association of Mb expression and intracellular 
fatty acid levels, we used the FASN inhibitor C75. This inhibitor has been characterized 
as FASN specific, leading to an almost immediate and irreversible enzyme inhibition 
(Kuhajda et al, 2000).  In MDA-MB468 cells, we observed a strong time dependent down-
regulation of Mb on transcript  (Fig. 3D, left) and protein level (Fig. 3D, right) upon FASN 
inhibition in comparison to control cells, suggesting that non-muscle Mb expression is 
indeed regulated by intracellular fatty acid levels. Thus, Mb in breast carcinomas and 
cancer cells might be involved in controlling fatty acid metabolism. 
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4. Discussion 
This report is the first systematic examination of myoglobin (Mb) expression in a 
large cohort of breast cancer specimens that allows clinical and molecular correlations 
and furthermore points to unexpected functional facets of this hemoprotein. We first 
noticed a supposedly aberrant Mb immunoreactivity in a small series of breast 
carcinomas. To address whether Mb is being actively produced by breast cancer cells or, 
rather taken up from e.g. adjacent musculature as suggested  by Eusebi et al. more than 
25 years ago (Eusebi et al, 1984), we analyzed its expression both in vitro and in vivo. On 
transcript level, we found Mb strongly upregulated in breast tumors in comparison with 
adjacent normal ductal tissue. Mb mRNA was also detectable in breast cancer cell lines, 
in a small subset even at surprisingly high levels. This underscored the active expression 
of endogenous Mb in ordinary invasive ductal breast cancer, which were neither muscle-
invasive nor did they, as assessed by light microscopy, exhibited any rhabdomyogenous 
differentiation. Transmission electron microscopy did also not reveal any striated muscle 
elements in two strongly Mb positive breast cancer cases. We therefore conclude that Mb 
is de novo expressed in breast cancer cells although rare cases of so-called metaplastic 
carcinomas of the breast might exist where Mb-positivity stems from the 
rabdomyogenous differentiation of the cells (Jamieson & Rudland, 1990; Yang et al, 
2003). 
On the basis of these encouraging preliminary findings, a large recently described 
(Theurillat et al, 2007) cohort of primary breast cancer including 917 invasive carcinomas 
and 155 cases of Ductal Carcinoma in situ (DCIS) was analysed for Mb expression. 
Specificity of the Mb antibody was confirmed through the peptide blockage of the 
immunohistochemical signal (Fig. S1). In total, 40% of invasive carcinomas showed 
moderate to strong Mb expression and the rate is even slightly higher in DCIS. However, 
Mb was also consistently seen in mature secretory epithelia of the healthy breast showing 
a basal expression in most cells with a particularly pronounced expression in estrogen 
receptor alpha (ER) positive cells, as we noted later. Contrary to earlier reports that 
found normal epithelia invariably Mb negative (Flonta et al, 2009), luminal cells in healthy 
breast clearly have the ability to express Mb at detectable levels. The recently published 
study of Flonta et al., that came out during the preparation of this manuscript, identified 
endogenous Mb in various human cancer cell lines and human epithelial tumors including 
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breast cancer and elucidated several signals including nitric oxide, oxidative stress and 
mitogens (EGF and serum growth factors) but also hypoxia, that were able to stimulate 
Mb expression in cultivated MCF7 breast cancer cells (Flonta et al, 2009). However, their 
study, which encompassed only 31 breast cancer cases, lacked any prognostic or 
detailed clinico-pathological data. 
Regarding its occurrence in breast cancer, we found that Mb is preferentially 
detected in better differentiated, hormone receptor positive tumors and is associated with 
a significantly better prognosis. All these features are characteristics of the so called 
luminal subtype of breast cancer according to Perou et al. (Perou et al, 2000) which 
shares many molecular similarities with normal secretory epithelia including a strong 
expression of cytokeratins typical of mature secretory epithelia (CK8/18), hormone 
receptor (ER/PR) positivity and negativity for HER2 and the basal cell cytokeratins 
CK5/6. Further support for considering Mb a diagnostic marker of the luminal breast 
cancer subtype comes from the in silico analysis of Farmer et al.’s data, in which Mb 
transcript levels were highest in tumors classified as the luminal subtype (Farmer et al, 
2005). Our immunofluorescent double stainings further detected co-localisation of 
cytoplasmic Mb and nuclear ER in secretory cells of normal breast tissue. The same 
intracellular co-localization was found in strongly Mb and ER-positive invasive ductal 
carcinomas. Beyond this spatial co-existence, Mb and ER transcripts are also co-
ordinately and dose-dependently down-regulated when MCF7 cells are subjected to an 
estrogenic (E2 = 17--estradiol) treatment protocol as demonstrated by in silico (Fig. S5) 
and in vitro (Fig. 3B) analyses. In this context it is of relevance to highlight the observation 
of Cheng et al., who described the inverse relationship of E2 and ER (which we found 
co-expressed with Mb) levels in normal breast epithelia during the mammalian menstrual 
cycle (Cheng et al, 2005). These authors further point out that elevated expression of 
ER, occurring, for example, in postmenopausal women as a result of the loss of E2 
signaling, is indicative for non-proliferating breast cells. The hitherto undescribed co-
regulation of Mb with ER by estrogen likely underlies the co-expression of ER with Mb 
in differentiated luminal cells with their reduced proliferation, which, in turn, might explain 
the favorable prognosis of Mb positive tumors. The negative association of tumoral Mb 
expression and a pre-menopausal status further fits the interpretation of Mb as an 
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estrogen silenced gene, since premenopausal patients (high estrogen serum levels) have 
in comparison to postmenopausal patients (lower estrogen serum levels) tumors with 
lower Mb expression levels. In any instance, since the prognostic value of Mb is limited in 
comparison to ER or PR, we do not suggest its use as a primary marker to identify 
luminal phenotype carcinomas for therapy planning. However, Mb might gain clinical 
relevance if it could be validated as a novel therapy target of cancer, e.g. by applying 
carbon monoxide in sub-toxic concentrations, as has been suggested by Dr. Wittenberg 
at the O2BIP meeting in Aarhus in 2008, which clearly warrants further study. This is the 
more important, since luminal type breast cancer, although generally more favourable in 
course, does not respond well to conventional chemotherapy (Bhargava et al). 
Mb has different known or alleged functions in muscle tissue including short-term 
O2 storage and buffering, facilitating O2 diffusion, scavenging of NO and ROS and also 
the reverse (peroxidase activity, NO production) and might be involved in fatty acid 
metabolism (Flögel et al, 2004; Flögel et al, 2001; Hendgen-Cotta et al, 2008; Khan et al, 
1998; Masuda et al, 2008; Ordway & Garry, 2004; Wittenberg et al, 1975; Wittenberg, 
1970).  The functions of Mb in non-muscle tissues are elusive so far. More than 50 years 
after Thomlinson’s and Gray’s pioneering discovery to link radiosensitivity with oxygen 
tension in tumor tissue (Gray et al, 1953; Thomlinson & Gray, 1955), the existence of 
regional hypoxia in most solid tumors (for review: (Brown, 1999; Brown & Wilson, 2004; 
Thews et al, 1998; Vaupel et al, 1991) including breast cancer is of high clinical relevance 
(Vaupel et al, 1992). Using the exogenous hypoxia marker pimonidazole Arcasoy et al. 
concluded from a series of 26 breast cancer cases that 62% of tumors of the breast are 
pimonidazole-positive and thus hypoxic (Arcasoy et al, 2002). Since this rate of positivity 
is in the range of Mb positivity we observed in breast cancer, we had originally 
hypothesized to find an association of Myoglobin with tissue hypoxia. Also, the 
demonstration of hypoxia driven Mb induction in a cell line model by Flonta et al. fitted 
this interpretation very well (Flonta et al, 2009). However, our in vivo data, correlating Mb 
expression with acknowledged endogenous markers of hypoxia, revealed a rather more 
complex and heterogeneous picture. There was no correlation with HIF-1 and its target 
gene GLUT1 which could either mean that Mb is not significantly regulated by hypoxia in 
vivo or that HIF-1 is insufficiently present and active due to the amelioration of tissue 
hypoxia by expressed Mb. However, given the picomole concentrations of Mb protein we 
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have measured per million of  the maximal Mb-producing MDA-MB468 cell line (Fig. 1B), 
the latter scenario is rather unlikely to explain this lack of correlation. On the other hand, 
there is a significant correlation of Mb to HIF-2 and the HIF-1/-2 target gene CAIX, 
which is in line of at least a partial control of Mb expression by hypoxia. Yet, expression of 
Mb in breast epithelia can clearly be regulated irrespective of oxygen levels (i.e. signals in 
normal secretory ductal cells). The fact that Mb in breast malignancies links with HIF-2 
rather than HIF-1 results perhaps from the mutually exclusive status between active 
HIF-1 and ER/PR signalling in breast cancer cells (Kurebayashi, 2003; Massaad-
Massade, 2004). In this sense, it is the positive correlation between Mb and ER/PR 
positivity which might preclude a significant linkage of Mb with HIF-1All this evidence 
only underscores the complex regulation of the Mb gene in breast carcinomas, where 
hypoxia/HIF signaling is just one of several stimuli to modulate the abundance of this 
hemoprotein. 
To our knowledge, so far only two studies have investigated the functions of 
myoglobin in in vivo models using artificial Mb expression systems. Nitta et al. induced 
Mb expression in hepatocytes by an adenoviral gene transfer in rodents, with the effect, 
that these hepatocytes were significantly more hypoxia resistant (Nitta et al, 2003). 
Galluzzo et al. were the first to introduce Mb into tumor cell lines and engineered A549 
human lung carcinoma cells to ectopically express mouse Mb (Galluzzo et al, 2009). 
Their experimental Mb expressing tumors displayed reduced or no hypoxia, minimal HIF-
1 levels, decreased vessel density and finally a more differentiated cancer cell 
phenotype. Also, largely suppressed local and distal metastatic spreading was observed. 
The authors assume that these beneficial outcomes of Mb over-expressing tumors result 
primarily from the reduction of tumor hypoxia (Galluzzo et al, 2009). Although it is 
tempting to compare their mouse model in vivo findings with our in vivo observations from 
human patients, given that higher Mb levels correlate with less aggressive tumor 
behavior, both situations are quite different. We have estimated the amount of 
endogenous Mb in normoxic MDA-MB468 breast cancer cells to equate to ~65 ng or 4 
pmol of Mb protein present in 106 cells. This quantity is certainly far below the high M 
levels reached by the lentiviral gene transfer (Galluzzo et al, 2009). While such excessive 
amounts of ectopic Mb in tumor cells can with reason be assumed to have a significant 
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impact on tumor respiration and tumor growth, the endogenous picomole quantities of Mb 
we detected are unlikely to confer meaningful O2 storage/buffering capacity to the cell, as 
already mentioned above. Thus, for these cells, functions of Mb that are not directly 
linked to the binding and transport of O2 have to be considered to understand the 
physiological relevance of this protein in breast cancer. 
One of these functions of Mb that might also be tremendously relevant for tumor 
cells is the control of fatty acid metabolism. In a multitude of tumors, growth is 
accompanied with increased fatty acid synthesis and consequently enzymes catalyzing 
these steps are up-regulated and can be used diagnostically and therapeutically (for 
recent reviews see (Mashima et al, 2009; Menendez & Lupu, 2007)). The co-localization 
of Mb with fatty acid synthase (FASN) we discovered might give a hint towards the fatty 
acid binding function of tumor Mb. Fatty acid binding properties of Mb have been reported 
and predicted early (Gloster & Harris, 1977; Lewis et al, 1968) and have recently gained 
further attention (Sriram et al, 2008). According to Flögel and colleagues, lack of Mb in 
the heart of knockout mice leads to a biochemical shift in cardiac substrate utilization from 
fatty acid to glucose oxidation which, not only corresponds to an adaptive reduction in O2 
consumption for the equimolar production of ATP, but more so implicates the protein in 
providing fatty acid substrates for the mitochondrial-oxidation breakdown in vivo (Flögel 
et al, 2005). Our indirect demonstration, that Mb is likely to be regulated by intracellular 
fatty acid levels as shown by the inhibition of fatty acid synthase (FASN) now indicates a 
putative role for Mb in fatty acid metabolism of cancer cells and clearly warrants further 
study. Analysing the metabolomic profiles of Mb positive and negative breast cancer 
cases should also yield relevant data to shed more light on the putative role of Mb in fatty 
acid metabolism. 
In summary, Mb is endogenously expressed in normal breast tissue and 
abundantly in a subset of breast cancer cases. The strong association of Mb expression 
with presence of the estrogen receptor (ER) explains the generally better prognosis of 
Mb positive tumors, compared to tumors lacking Mb. It appears, that the regulation of Mb 
in tumors is so far only incompletely understood. Our data suggests that in breast cancer 
cells, Mb expression is regulated by estrogen signaling, possibly also by fatty acid levels 
and hypoxia. Mb`s prospective role in the lipid metabolism of ER-positive tumors provides 
a reasonable rationale to investigate this association in further studies, yet the role of 
  
 
18
other stimuli, e.g. nitric oxide or growth factors also needs to be looked at in greater 
detail. Taken together, these findings further broaden our view on the role of non-muscle 
Mb that may have fundamental implications for our conception of the biology of solid 
tumors.  
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 Table 1 Clinico-pathological parameters of invasive breast cancer cases and relation to 
myoglobin expression  
Characteristic Number of 
cases (%) 
MB  
negative 
MB 
weak 
MB 
moderate 
MB 
strong 
p-value 
 917 (100%)      
<60 years 416 (45.4%) 125 132 130 29 
>=60 years 501 (54.6%) 142 157 142 60 
0.170# 
Pre-menopausal 198 (21.5%) 67 64 60 7 
Post-menopausal 719 (78.5%) 200 225 212 82 
0.007# 
Invasive ductal 739 (80.6%) 214 221 228 76 
Invasive lobular 
125 (13.6%) 39 49 29 8 
NOS 
53 (5.8%) 14 19 15 5 
0.375* 
pT1 335 (36.5%) 91 108 106 30 
pT2 410 (44.7%) 115 134 119 42 
pT3 66 (7.2%) 27 19 17 3 
pT4 106 (11.6%) 34 28 30 14 
0.479# 
pN0 346 (42.5%) 92 107 111 36 
pN1 369 (45.3%) 113 120 105 31 
pN2 69 (8.5%) 21 20 16 12 
pN3 31 (3.8%) 10 8 12 1 
0.355# 
G1  126 (13.7%) 30 40 46 10 
G2  460 (50.2%) 112 155 141 52 
G3  331 (36.1%) 125 94 85 27 
0.001# 
ER-negative 163 (18.7%) 78 45 34 6 
ER-Positive 709 (81.3%) 171 226 231 81 
0.001# 
PR-negative 314 (34.8%) 114 104 82 14 
PR-positive 588 (65.2%) 145 183 187 73 
0.001# 
HER2 0, 1+,2+, 776 (88.1%) 223 241 239 73 
HER2 3+ 105 (11.9%) 33 37 25 10 
0.346# 
  Ki-67 <=10% 466 (54%) 132 149 139 46 
Ki-67 >10%   393 (46%) 117 115 121 40 
0.985# 
CK5/6 neg. 793 212 260 239 82 
CK5/6 pos. 96 45 22 26 3 
0.001# 
* Pearson Chi-Square, # Chi-Square for trends 
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Table 2 Correlation of Myoglobin expression to endogenous Markers of hypoxia (CC; p-
value) 
 HIF-1 HIF-2 GLUT1 CAIX 
Mb 0.095; 0.276 0.293; 0.001 -0.039; 0.64 0.286; 0.001 
HIF-1  0.215; 0.020 0.334; 0.001 0.285; 0.001 
HIF-2   -0.206; 0.024 0.223; 0.015 
GLUT1    0.252; 0.003 
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Figure legends 
Figure 1. Detection of Mb mRNA and protein in clinical breast cancer samples and cell 
lines 
A) Myoglobin mRNA expression in ten randomly chosen samples of human breast cancer 
and corresponding normal breast tissues (#1 to #10) as measured by quantitative RT-
PCR. Calculation of error bars according to Applied Biosystems user manual. Median 
myoglobin expression was up to 352-fold up-regulated in breast tumors (gray) compared 
to matching normal breast tissues (white). B) Myoglobin mRNA expression in benign 
MCF12A breast cells and various breast cancer cell lines. C) Normal lobular parenchyma 
of the breast, illustrating a mild Mb immunoreactivity in luminal epithelial cells (inner layer, 
thin arrow), whereas myoepithelial cells (outer cell layer, arrowhead) are negative. Note, 
that single luminal cells (bold arrow) are highlighted by a stronger Mb immunostaining 
(400x). D) Strong myoglobin positivity in a ductal carcinoma in situ (DCIS), low grade, 
showing a slight accentuation of staining in the center in support of O2-diffusion gradients 
contributing to the Mb expression profile in tissues (200x). E/F) Examples of invasive 
ductal carcinoma of the breast (all 200x). E) Moderately differentiated with a moderate to 
strong and patchy Mb expression. Note also the central normal duct (arrow) with the Mb 
positive secretory cell layer and the Mb negative myoepithelial layer. F) Strong Mb 
immunoreactivity in a well differentiated carcinoma. 
 
Figure 2. Mb expression is linked to better prognosis and ER-positivity and inversely 
related to estrogen concentration 
A) Kaplan Meier analysis of a cohort of 917 primary breast cancer cases showing that 
tumors with high Mb expression (Mb+) demonstrate a significant prognostic value for the 
patient of an improved cumulative overall survival compared to cases with low Mb 
expression (Mb-). B) Myoglobin expression in MCF7 breast cancer cells is repressed by 
increasing concentrations of 17-ß-estradiol (dissolved in ethanol) as measured by 
quantitative RT-PCR.  C) normal breast tissue (left) shows a weak immunofluorescence 
for Mb in the secretory cell layer, of which some stronger staining cells are intermingled. 
D) The immunofluorescence for ER (left) shows a nuclear staining also of single cells. 
E)The merged Figure (left) illustrates, that these cells highlighted by ER and Mb are 
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mostly corresponding (all 400x). C-E) This co-expression is also shown in a well 
differentiated invasive ductal breast carcinoma (panel on right hand side) (all 200x). 
 
Figure 3. Double immunofluorescence (Mb/FASN) staining of breast tissues and 
regulation of Mb by inhibition of FASN 
A) Normal breast tissue (panel on the left) shows weak immunofluorescence for Mb in the 
secretory cell layer, along with some stronger staining cells are intermingled. B) The 
immunofluorescence for FASN (middle) shows strong cytoplasmic staining. C) The 
overlay Figure (bottom) illustrates high degree of correspondence (yellow) between cells 
expressing Mb and FASN (all 400x). In invasive carcinomas (panel on the right), a greater 
variation is seen and co-expression of Mb and FASN is only preserved in a subset of cells 
as the overlay illustrates. In general, the FASN expression exceeds Mb immunoreactivity 
(all 200x).  D) RT-PCR evidence for C75-mediated downregulation of Mb mRNA (left). 
Western blot evidence for C75-mediated downregulation of Mb protein (right).
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Supplemental Legends. 
Fig. S1. Establishment of a sensitive and specific immunohistochemistry protocol to 
detect myoglobin 
Three different myoglobin antibodies were compared for their suitability to detect 
myoglobin in formalin fixed paraffin embedded (FFPE) tissues, i.e. mouse monoclonal 
clone z001, Zymed, USA; mouse monoclonal clone MG1, Neomarkers, USA and rabbit 
polyclonal anti-human myoglobin, DAKO, Denmark. All three antibodies yielded 
comparable results with clone z001 showing the cleanest immunoreactivity. To further 
enhance sensitivity a heat induced epitope retrieval (HIER) step was included in the z001 
detection protocol (left). A blocking experiment with purified human myoglobin (1:10 mol) 
confirmed the specificity of the immunoreaction (right). 
 
Fig. S2. Mb immunohistochemistry – distribution of expression during tumor progression 
The distribution of intensity of Mb immunoreactivity, categorized as negative (green), 
weakly (yellow), moderately (orange) and strongly positive (red) in normal breast tissues, 
DCIS, invasive breast cancer and recurrences of invasive breast cancer is shown. 
Clearly, on average no simple down or upregulation ob Mb expression is noted, but a 
polarization with increasing losses and gains in intensity of Mb expression with tumor 
progression is apparent. 
 
Fig. S3. Transmission electron microscopy of two Mb positive breast cancer specimens 
Since myoglobin has been described as a marker of rhabdomyoid differentiation, two 
breast tumors with strong myoglobin immunoreactivity were analysed by transmission 
electron microscopy. A) Cell of an invasive lobular carcinoma with broad bundles of 
intermediate filaments (arrow). B) Cell of an invasive ductal carcinoma exhibiting a 
plethora of endoplasmatic reticulum. No striated muscle elements as exemplified in C) 
(human heart muscle) were noted. 
 
Fig. S4. Kaplan Meier Analysis of overall survival of 872 breast cancer patients with 
respect to Mb and ER status 
This figure illustrates the additive prognostic value of Mb and ER by comparing tumors 
negative for ER and MB (half-dotted line), tumors positive for ER and Mb (full line) and 
  
 
28
tumors which are positive for either, ER or Mb (dotted line). Note, that the latter group that 
has positivity for one marker indicative for luminal phenotype does do considerably better 
than tumors negative for both, however, it does not quite reach the relatively favourable 
course of the group in which both markers are positive. 
  
 
Fig. S5. In silico analysis of the influence of estrogen signaling on Mb and ESR1 in MCF-
7 cells 
Retrieving the array datasets of Coser et al. (2003) via the web based data mining tool 
GEO Profiles, two experiments were analysed. On the left, the influence of estrogen 
starvation on the expression of Mb and ESR1 (=ER) is illustrated. Clearly, a concomitant 
up-regulation of both transcripts (single channel counts, red bars) during 48h is apparent. 
Conversely, the profiles of MCF-7 cells that were treated with 17-β-estradiol (on the right) 
show a dose dependent down-regulation of Mb and ESR1. Note, however, that the 
amplitude of either ESR1 regulation (red bars) is artificially enhanced due to the start of 
Y-axis labels at non-zero values (explains poor correspondence with blue percentile rank 
data in ESR1 profiles). 
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